2021 High quality Colloidal Gold (LFA) - COVID-19 IgM/IgG Lateral Flow Assay – Genobio


Product Detail

Product Tags

Related Video

Feedback (2)

It can be our duty to satisfy your preferences and successfully serve you. Your pleasure is our best reward. We have been looking forward to the go to for joint expansion for Carbapenem-resistant OXA-23 Detection K-Set (Lateral Flow Assay), candida IgM, Interleukin-6 test, Our group members are goal to provides merchandise with significant performance cost ratio to our consumers, as well as target for all of us is usually to satisfy our consumers from all around the environment.
2021 High quality Colloidal Gold (LFA) - COVID-19 IgM/IgG Lateral Flow Assay – Genobio Detail:

Product Introduction

Virusee® COVID-19 IgM/IgG Lateral Flow Assay is a lateral flow immunoassay used for in vitro qualitative detection of novel coronavirus (SARS-CoV-2) IgM / IgG antibodies in human venipuncture whole blood, plasma, and serum specimens.

The novel coronavirus is a positive single-stranded RNA virus. Unlike any known coronavirus, the vulnerable population for Novel Coronavirus is generally susceptible, and it is more threatening to the elderly or people with fundamental diseases. IgM/IgG antibodies positive is an important indicator of novel coronavirus infections. Detection of novel coronavirus-specific antibodies will aid clinical diagnosis.

Characteristics

Name

COVID-19 IgM/IgG Lateral Flow Assay

Method

Lateral Flow Assay

Sample type

Blood, plasma, serum

Specification

20 tests/kit

Detection time

10 min

Detection objects

COVID-19

Stability

The kit is stable for 1 year at 2-30°C

COVID-19 IgMIgG Lateral Flow Assay

Advantage

  • Rapid
    Obtain result within 10 min
  • Simple
    Visually reading result, easy to interpret
    Simple procedure, without complicated operation
  • Cost-saving
    Product can be transported and stored at room temperature, reducing costs
  • Low risk
    Testing blood sample, reducing the risk of sampling process
  • Suitable for screening on-site, bedside, outpatient

Background and principle

The novel coronavirus, severe acute respiratory syndrome coronavirus (SARS-CoV)-2, has been identified as the causative pathogen of coronavirus disease 2019 (COVID-19). This disease has been called a public health emergency of international concern by the World Health Organization (WHO).

COVID-19 targets the upper and lower respiratory systems and causes flu-like symptoms in most infected people. Although many COVID-19 patients experience only mild symptoms, some patients have severe symptoms leading to massive lung damage. Treatment options for COVID-19 are limited and the crude mortality rate estimated by the WHO is around 2.9%. Although a preventive vaccine for COVID-19 could eventually become available, unless sufficient herd immunity is achieved, COVID-19 could potentially cause significant morbidity and mortality over the coming years.

After suffering from an infection, it is common to develop an antibody response against a particular pathogen. Early after infection (usually after the first week), a class of antibodies known as immunoglobulin M (IgM) develops, although these are not typically long-lasting. Later, after the first 2-4 weeks following infection, IgG, a more durable antibody, is produced.

Studies have found that RBD-targeted antibodies are excellent markers of previous and recent infection, that differential isotype measurements can help distinguish between recent and older infections. The detection of IgM and IgG antibodies against SARS-CoV-2 has potential significance for evaluating the severity and prognosis of COVID-19, and even increasing the detection accuracy of nuclear acid test.

The detection of SARS-CoV-2 IgM and IgG is very important to determine the course of COVID-19. Nucleic acid detection combined with serum antibody of SARS-CoV-2 may be the best laboratory indicator for the diagnosis of SARS-CoV-2 infection and the phrase and predication for prognosis of COVID-19.

COVID-19 IgG Lateral Flow Assay 1
COVID-19 IgG Lateral Flow Assay 2

Test process

COVID-19 IgMIgG Lateral Flow Assay 3

Order Information

Model

Description

Product code

VMGLFA-01

20 test/kit, cassette format

CoVMGLFA-01


Product detail pictures:

2021 High quality Colloidal Gold (LFA) - COVID-19 IgM/IgG Lateral Flow Assay – Genobio detail pictures

2021 High quality Colloidal Gold (LFA) - COVID-19 IgM/IgG Lateral Flow Assay – Genobio detail pictures

2021 High quality Colloidal Gold (LFA) - COVID-19 IgM/IgG Lateral Flow Assay – Genobio detail pictures


Related Product Guide:

"Control the standard by the details, show the power by quality". Our business has strived to establish a highly efficient and stable team staff and explored an effective good quality regulate course of action for 2021 High quality Colloidal Gold (LFA) - COVID-19 IgM/IgG Lateral Flow Assay – Genobio , The product will supply to all over the world, such as: Serbia, Mali, Canberra, Our company absorbs new ideas, strict quality control, a full range of service tracking, and adhere to make high-quality solutions. Our business aims to "honest and trustworthy, favorable price, customer first", so we won the trust of the majority of customers! If you are interested in our items and services, please do not hesitate to contact us!
  • Perfect services, quality products and competitive prices, we have work many times, every time is delighted, wish continue to maintain!
    5 Stars By Elma from Germany - 2017.08.18 11:04
    In our cooperated wholesalers, this company has the best quality and reasonable price, they are our first choice.
    5 Stars By Monica from Botswana - 2017.06.16 18:23
    Write your message here and send it to us